Big Pharma will muscle in on obesity gold rush
28/11 15:47
LONDON (Reuters Breakingviews) - Obesity drugs are a modern day gold rush for drugmakers. Eli Lilly, valued at $347 billion, is close behind $207 billion Novo Nordisk in releasing a weight loss drug, in a market expected to be worth $50 billion...